TARGAN Secures $35M Series C Financing Led by Mountain Group Partners and NovaQuest Capital Management to Commercialize Novel Vaccine Delivery System for Poultry Industry
Retrieved on:
Wednesday, May 25, 2022
Professional Services, Health, Finance, Managed Care, Pharmaceutical, Biotechnology, MSD, Virulent Newcastle disease, Poultry, Population, Sex, Caldwell, MGP, Oval Park, Visalia, California, Health, Meat, Investment, Merck & Co., Vaccine, Solution, Science, List of life sciences, Partnership for a Healthier America, Wernecke Mountains Group, Avian infectious bronchitis, Animal Health, Farmer, Robotics, Artificial intelligence, Vaccination, Technology, Research, PC, Industry, Partnership, Food, Intellectual property, Instagram, Microfluidics, Human, Medtech, University of Veterinary and Animal Sciences, Schering-Plough, Specialization, Therapy, LinkedIn, Animal, Twitter, Growth, Coccidiosis, Caliper Life Sciences, CEO, Pharmaceutical industry, Renewable energy, Fine chemical, Aquaculture, Merck, Facebook, Lead, Diagnosis, Series
The financing was co-led by Mountain Group Partners and NovaQuest Capital Management.
Key Points:
- The financing was co-led by Mountain Group Partners and NovaQuest Capital Management.
- TARGAN integrates its proprietary technologies consisting of high-speed imaging, feature recognition, artificial intelligence, robotics, and microfluidics in a system currently developed for the commercial poultry industry.
- The Series C investment will allow TARGAN to accelerate the commercialization of its automated and individualized poultry vaccination and gender identification systems.
- We are most delighted that our great progress has led to NovaQuest joining our existing investors in this series.